Rafael Holdings Completes Cyclo Therapeutics Merger

Introduction

Rafael Holdings, Inc. (NYSE: RFL) is a clinical-stage biotechnology company focused on developing treatments for challenging diseases. The company utilizes a portfolio approach, investing in therapeutic candidates and subsidiaries across the rare-disease, oncology, and medical-device sectors.

Corporate Structure

Rafael Holdings operates through a wholly-owned subsidiary model. On March 26, 2025, it completed a merger with Cyclo Therapeutics, Inc., making Cyclo a wholly-owned subsidiary focused on its lead asset, Trappsol® Cyclo™. Other holdings include:

• LipoMedix Pharmaceuticals, Ltd. (clinical-stage therapeutics)
• Barer Institute, Inc. (preclinical cancer metabolism research)
• Cornerstone Pharmaceuticals, Inc. (cancer metabolism-based therapeutics)
• Rafael Medical Devices, LLC (orthopedic instruments)
• Day Three Labs, Inc. (pharmaceutical-grade cannabis technology)

In an S-8 filing dated June 26, 2025, Rafael registered 1,393,077 Class B shares for two equity incentive plans, reflecting amendments related to the Cyclo merger and ongoing employee retention efforts. Leadership includes Chairman Howard S. Jonas, President and CEO Bill Conkling, and CFO David Polinsky.

Biotechnology by National Cancer Institute

Developments and News

• March 26, 2025: Merger with Cyclo Therapeutics closed. Rafael issued Class B shares and warrants to Cyclo shareholders.
• Mid-2025: Results from the TransportNPC™ Phase 3 trial (Niemann-Pick Disease Type C1) 48-week interim analysis are expected.
• June 11, 2025: Form 10-Q filed covering the quarter ended May 31, 2025.
• June 18, 2025: Form 8-K filed disclosing Regulation FD communications and other material events.
• June 26, 2025: S-8 prospectus registered shares for the 2021 Equity Incentive Plan and the Cyclo Omnibus Equity Plan.
• July 10, 2025: Stock closed at $2.24 per share, reflecting a 19.15% increase on a volume of 1,507,243 shares (average volume: 179,539).

Financial and Strategic Analysis

As of the quarter ended May 31, 2025:

• Market cap: $76.7 million; enterprise value: $39.5 million
• Revenue (ttm): $0.73 million; net loss: $22.9 million (EPS: –0.92)
• Price/Sales: 70.15; Price/Book: 0.93; EV/Revenue: 53.93
• Cash: $37.9 million; debt/equity: 0.82%

In June 2025, Rafael completed a $25 million rights offering, raising net proceeds of $24.9 million, with CEO Howard Jonas and affiliates backstopping unsubscribed shares. These funds are allocated for regulatory submissions and the potential launch of Trappsol Cyclo, contingent on favorable interim trial results.

Market Position and Industry Context

Rafael Holdings operates within the clinical-stage biotech sector, focusing on rare and life-threatening conditions. Its lead candidate, Trappsol Cyclo, has received orphan-drug designation in the U.S. and EU for Niemann-Pick Disease Type C1. The company's diversified interests across oncology, rare-disease therapeutics, and medical devices help mitigate pipeline risks. The increase in share price and trading volume on July 10, 2025, reflects investor interest in the upcoming interim analysis and the strengthened balance sheet following the rights offering.

TL;DR

• Merger with Cyclo Therapeutics closed on March 26, 2025, with Trappsol Cyclo as Rafael’s lead program.
• Results from the TransportNPC Phase 3 interim data are expected mid-2025.
• June 2025 rights offering raised $24.9 million to support approval efforts and potential product launch.
• Shares increased 19.15% to $2.24 on July 10, 2025, amid above-average trading volume.